Lurje Georg, Bednarsch Jan, Czigany Zoltan, Amygdalos Iakovos, Meister Franziska, Schöning Wenzel, Ulmer Tom Florian, Foerster Martin, Dejong Cornelis, Neumann Ulf Peter
Department of Surgery and Transplantation, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany.
Department of Surgery, Maastricht University Medical Centre (MUMC), Maastricht, Netherlands.
Langenbecks Arch Surg. 2018 Nov;403(7):851-861. doi: 10.1007/s00423-018-1715-9. Epub 2018 Sep 28.
Tumor recurrence after liver resection continues to pose a major problem in hepatocellular carcinoma (HCC). Here we aimed to evaluate prognostic markers for disease-free (DFS) and overall survival (OS) in HCC-patients who underwent liver resection in curative intent. Additionally, we investigated the effects of HCC-recurrence in a subgroup of patients.
Between 2010 and 2016, 111 patients underwent surgical resection for HCC at our institution. A subgroup of 50 patients showed tumor recurrence (n = 50) during follow-up. The associations of DFS and OS with histopathologic characteristics were assessed using univariable and multivariable Cox regression analyses.
Median DFS was 31 months and median OS was 27 months. Milan criteria (p = 0.045), macrovascular invasion (p = 0.044) and UICC tumor stage (p = 0.003) were independently associated with DFS while macrovascular invasion (p = 0.001) and MELD score (p = 0.010) were independently associated with OS. Tumor recurrence did not show an association with OS (p = 0.228). However, patients with HCC-recurrence who underwent repeat-surgical or interventional treatment showed improved OS compared to patients treated with palliative or sorafenib treatment alone (OS 18 months vs. 2 months; p < 0.001).
Tumor recurrence alone is not associated with poor oncological outcome and repeat liver resections as well as local-ablative procedures may help to improve OS in HCC.
肝切除术后肿瘤复发仍是肝细胞癌(HCC)的一个主要问题。在此,我们旨在评估接受根治性肝切除的HCC患者无病生存期(DFS)和总生存期(OS)的预后标志物。此外,我们还研究了HCC复发在部分患者亚组中的影响。
2010年至2016年间,我院111例患者接受了HCC手术切除。50例患者的亚组在随访期间出现肿瘤复发(n = 50)。采用单变量和多变量Cox回归分析评估DFS和OS与组织病理学特征的相关性。
DFS中位数为31个月,OS中位数为27个月。米兰标准(p = 0.045)、大血管侵犯(p = 0.044)和国际抗癌联盟(UICC)肿瘤分期(p = 0.003)与DFS独立相关,而大血管侵犯(p = 0.001)和终末期肝病模型(MELD)评分(p = 0.010)与OS独立相关。肿瘤复发与OS无相关性(p = 0.228)。然而,与单纯接受姑息治疗或索拉非尼治疗的患者相比,接受再次手术或介入治疗的HCC复发患者的OS有所改善(OS为18个月对2个月;p < 0.001)。
单纯肿瘤复发与不良肿瘤学结局无关,再次肝切除以及局部消融手术可能有助于改善HCC患者的OS。